M&A Deal Summary |
|
|---|---|
| Date | 2012-10-30 |
| Target | Nabi Biopharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Aviragen Therapeutics |
| Deal Type | Add-on Acquisition |
| Deal Value | 100M USD |
SEARCH BY
| Category | Company |
|---|---|
| Sector | Life Science |
| Employees | 19 |
Aviragen Therapeutics, Inc. is a developer of innovative products for the prevention and treatment of serious and potentially life-threatening infectious diseases.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| State: Maryland M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2012 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-06-03 |
Anaconda Pharma SAS
Paris, France Anaconda Pharma SAS is a biotechnology company. |
Buy | - |